Variants in GLP1R, GIPR, FTO, and MC4R determine whether semaglutide's single-pathway approach or tirzepatide's dual mechanism will activate your weight loss biology most effectively, guiding your PlexusDx clinician toward the optimal starting medication
Oral tirzepatide works by slowing stomach emptying and signaling satiety to your brain, but when you take it matters just as much as what you take
Tirzepatide is a 39-amino-acid dual agonist that binds both the GIP and GLP-1 receptors from a single peptide backbone, with a C20 fatty-diacid moiety that extends its half-life in solution
In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Grossman A, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Stratakis CA, Trence DL, Wilson DP, eds
The clinical trial evidence on duration The landmark STEP trials for semaglutide and SURMOUNT trials for tirzepatide provide the clearest data on what happens at different treatment durations
Patients located in Florida who prefer ongoing care often choose the monthly plan for both savings and consistency
